<DOC>
	<DOCNO>NCT02869048</DOCNO>
	<brief_summary>Amyotrophic Lateral Sclerosis ( ALS ) aggressive , deadly disease . ALS lead destruction neural pathway control conscious movement muscle . This destruction lead muscular dystrophy increase difficulty move , breathe , swallow , speak . In last phase ALS patient 's life necessary respiratory therapy order breathe . In average ALS patient live 3 year time get diagnose . The cause disease still unknown currently treatment stop progression disease . Former clinical study indicate innate immune system particular complement system play significant role progression ALS . The complement system , activate cascade , part innate system participate innate well acquire immune system . Former clinical trial characterize limited knowledge complement system well measure . Today possible measure directly different component complement system understand contribution overall immune response . It also possible today detect defect complement system . All progression foundation project carry close cooperation one world 's leading researcher complement system , professor Peter Garred Rigshospitalet . The aim make national research project ALS order investigate role innate immune system , especially complement system , patient ALS . In long term hope , lead way target effective medical treatment people affect grave disease .</brief_summary>
	<brief_title>Amyotrophic Lateral Sclerosis Innate Immune System</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis ( ALS ) progressive , deadly , neurodegenerative disease affect upper low motor neuron . This lead profound muscular dystrophy , hyperreflexia , fasciculation paresis bulbar well skeletal musculature . ALS cause increase physical fatigue patient soon become bedridden respiratory insufficient.The diagnosis ALS make accord El Escorial revisit . Often clinical neurophysiological test must repeat ( 1-4 ) . In Denmark incidence ALS 1-2/100.000 prevalence 4-6/100.000 . The average survival time time diagnosis 3 year great variance . ( 5+6 ) Today pathogenesis still unknown treatment stop progression ALS . Treatment riluzole seem prolong median time survival 2 3 month ( 7 ) . Most likely , future medical treatment require well understanding pathogenesis well pathophysiology ALS . This present study aim base hypothesis ALS partially fully cause complement activation . The complement system complex system consist protein plasma well membrane bound proteins together complement antibody-based immune system . The complement system self-perpetuating cascade system activate different pathway . It work opsonisation complement protein bind microorganisms activate target granulocyte , monocyte macrophage . The complement system also cause cytolysis microorganism via MAC ( membrane attack complex ) activation mast cell . It also inactivate eliminates burn immune complex well perform apoptotic renovation . A recent pilot study Neuromyelitis Optica show complement system play central part pathogenesis disease previously wrongfully perceive early stage Disseminated Sclerosis . These finding result medical treatment anticomplement ( equlizumab ) promising result ( 8 ) . It possible similar pathogenetic mechanism could molecular basis ALS . Different research group try illuminate immune system involve progression ALS ( 9-35 ) . Several study support hypothesis complement system crucial importance onset progression ALS . ( 9-28 ) In several clinical trial ALS plasma conclude ALS plasma cytotoxic incubate healthy red blood cell healthy nerve tissue . Some research indicate cytotoxicity cause complement system . The result , however , reproduce consequently clinical trial . These trial conduct decade ago method detect complement activity limit . ( 9-14 ) Several animal trial indicate ALS start neuromuscular junction ( NMJ ) therefore consider distal axonopathy rather central neurological disease , today general perception ALS . ( 27-31 ) The purpose project The aim increase knowledge pathophysiology disease ALS possibly may lead u closer target medical treatment . The project group want investigate previously find , unique cytotoxicity ALS plasma retrieve ( 9-14 ) . If case , modern method today make possible detect whether immune system general , particular complement system , cause cytotoxicity . The establishment national research project ALS complement system make research biobank systematically collect blood spinal liquid ALS patient country ensure opportunity find complement system play role onset progression ALS . Furthermore pilot study conduct purpose investigate complement activity NMJ patient ALS show study ALS mouse . ( 28 ) The hypothesis 1 . ALS characterize abnormal immune response cytotoxicity increase complement activity plasma reveal following : 1 . Plasma patient ALS show increase haemolytic activity incubate red blood cell healthy subject . 2 . The complement activity increase plasma ALS patient compare plasma neurologically healthy subject subject neurological disease . 3 . The haemolytic activity plasma ALS patient correlate complement activity . 2 . Spinal liquid ALS patient contains increase complement activity compare spinal liquid neurologically healthy subject subject neurological disease . Patients , material method : Clinical trial 1 ( CT1 ) : Haemolytic activity complement system ALS plasma Number subject : 25 patient ALS , 25 patient neurological disease , 25 healthy volunteer The course CT1 : A blood sample take patient . The red blood cell liquid part blood , plasma , separate . The red blood cell different subject incubate subject plasma.The trial course repeat inactivation present complement system heat anti-complement . Clinical trial 2 ( CT2 ) : Case-control study aim map complement system Number subjects:100 patient ALS , 100 patient neurological disease 100 neurologically healthy patient The course CT2 : Blood sample cerebrospinal fluid prepare freeze research biobank . Then sample 3 group subject analyse compare focus complement system : The complement activation potential measure biological material . A cytokine profile make well map acute phase reactant multiplex assay . Furthermore RNA expression profile make cell pellet stabilise RNA later . Clinical trial 3 ( CT3 ) : The complement system ALS patient time - cohort study Number subjects:20 patient ALS ( subset CT2 ) The course CT3 : Every sixth month course CT2 repeat . The activity complement system patient ALS analyze disease progress . Clinical trial 4 ( CT4 ) : Searching complement activity NMJ ALS patient Number subjects:10 patient ALS The course CT4 : The muscle biopsy take immediately brought Dep . Pathology Rigshospitalet . Then thin layer tissue stain order analyze muscle fiber NMJ well detect presence complement activity . Conducting study The project consist four clinical trial . Inclusion subject do together staff ALS outpatient clinic hospital country subject control group include accord list inclusion site . Inclusion site : ALS outpatient clinic , Neurological clinic , Rigshospitalet Glostrup ( CT1+2+3+4 ) Contact : Chief physician Elisabeth Elmo Neurological Clinic , Rigshospitalet Glostrup ( neurological control group , CT1+2 ) Contact : Professor , Chief physician , dr.med . Rigmor Højland Jensen Neurosurgical Clinic , Rigshospitalet ( neurological control group , CT2 ) Contact : Professor , chief physician , dr.med . Marianne Juhler ALS outpatient clinic , Neurological Dep. , Bispebjerg Hospital ( CT2 ) Contact : Chief physician Merete Karlsborg ALS outpatient clinic , Neurological Dep. , Roskilde Hospital ( CT2 + 3 ) Contact : Chief physician Helle Thagesen ALS outpatient clinic , Neurological Dep. , Odense University Hospital ( CT2 ) Contact : Chief physician , dr.med . Matthias Bode ALS outpatient clinic , Neurological Dep. , Aarhus Hospital , Nørrebrogade ( Clinical Trial 2 ) Contact : Chief Physician , ph.d. Anette Torvin Gildhøj Private Hospital , Brøndby ( Neurologically healthy control group , Clinical Trial 2 ) Contact : Anaesthesiologist Niels Anker Pedersen Power calculation CT1 : Haemolytic activity complement system ALS plasma The study Overgaard et al . ( 18 ) find mean difference 0,20 ( SE 0,052 ALS group , N=20 , SD 0,22 ) absorbance ( 415 nm 5 hour incubation ) ALS patient healthy bioanalysts . With α=0,05 og beta=0,20 correspond power 0,80 need include 21 subject . As possible drop out technically fail consider test investigator choose include 25 subject group . ( 36 ) CT2 : Case-control study map complement system The number subject group case-control study calculate α=0,05 The investigator compare complement activation potential 3 group amount subject . In healthy subject complement activation potential 100 % normal area range 50-150 % prevalence low complement activation potential ( 50 % ) 10 % . With power =0,80 calculate necessary include 100 subject group . Hereby possible find statistically significant difference group correspond odds ratio 2,3 , would correspond 20 % ALS patient low complement activation potential cause increased complement activity . ( 36 ) CT3 : The complement system ALS patient time - cohort study This hypothesis generate study . It expect include 20 ALS patient cohort subset Clinical Trial 2 . As control group baseline neurologically healthy control group Clinical Trial 2 use . CT4 : Searching complement activity NMJ ALS patient There previous study describe complement activity NMJ living human . It therefore relevant make calculation power . Data processing CT1 : Haemolytic activity complement system ALS plasma Comparing degree haemolysis ALS patient control group t-test one way ANOVA use . For calculate cut-off value investigator use receiver operating characteristic ( ROC ) curve . CT2 : Case-control study map complement system Comparing concentration complement complement activation potential ALS patient control group t-test one way ANOVA use . In order calculate odds low complement activation potential ALS group compare control group investigator use logistic regression . For calculate cut-off value receiver operate characteristic ( ROC ) curve use . CT3 : The complement system ALS patient time - cohort study As Clinical Trial 2 . Furthermore , regression analysis complement activity function time since onset ALS , gender , age , subtype illness disease progression conduct . CT4 : Searching complement activity NMJ ALS patient As CT2 . The degree complement deposition muscle pathology describe qualitatively blind score `` normal '' , `` light degree '' `` severe degree '' change conduct . This compare quantitatively 2 x K table non-parametric statistic . Dissemination result The result project publish international peer review , journal . Both positive negative finding publish . Perspectivation With establishment big national ALS research biobank possible conduct many future research project . Continuous research ALS paramount ALS patient nationally well internationally order maintain hope efficient medical treatment aggressive disease find future .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<criteria>For ALS group : Diagnosed diagnose category `` certain ALS '' `` likely ALS accord El Escorial rev . diagnose criterion For Neurological control group : Referred neurological department examine chronic headache refer get lumbar perfusion test perform . For group ( Clinical study 23 ) : permanent contraindication lumbar puncture perform For Neurological control group : Known chronic inflammatory disease autoimmune disease . For healthy control group ( clinical study 1 ) : Known disease For healthy control group ( clinical study 1 ) : Taking daily medication For Neurologically healthy control group ( Clinical study 2 ) : Known neurological disease For Neurologically healthy control group ( Clinical study 2 ) : Known chronic inflammatory disease autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Biological Specimen Banks</keyword>
	<keyword>Innate Immunity</keyword>
	<keyword>Clinical Study</keyword>
	<keyword>Complement system protein</keyword>
	<keyword>Amyotrophic lateral sclerosis</keyword>
	<keyword>Neurodegenerative disease</keyword>
	<keyword>Motor neuron disease</keyword>
</DOC>